Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
Inventors
Lu, Wei • Dowling, Peter C. • Yuan, Rui Rong
Assignees
US Department of Veterans Affairs
Publication Number
US-9585932-B2
Publication Date
2017-03-07
Expiration Date
2026-05-01
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The described invention provides methods and kits for administering an EPO-derived peptide to a subject suffering from a neurodegenerative disease. The EPO-derived peptide delays the onset and/or progression of a neurodegenerative disease, limits cognitive impairment in, and prolongs the survival of, subjects suffering from a neurodegenerative disease.
Core Innovation
The described invention provides methods and kits for administering an EPO-derived peptide to a subject suffering from a neurodegenerative disease. This EPO-derived peptide delays the onset and/or progression of a neurodegenerative disease, limits cognitive impairment, and prolongs the survival of subjects suffering from such diseases.
The problem being solved arises from the complex and progressive nature of Alzheimer's disease and other neurodegenerative disorders, which lack effective therapeutic options or cures. Current treatments have resulted in failures, and there is a pressing need to develop alternative immune-modifying agents that can delay disease onset and progression due to issues like rampant inflammation and inadequate innate immune regulation in the brain.
Claims Coverage
The patent includes one independent claim focusing on a kit comprising a composition with a cyclic EPO-derived peptide. The inventive features emphasize the peptide composition and its formulation.
Kit comprising a composition with a cyclic EPO-derived peptide
The invention covers a kit that includes a composition comprising a cyclic EPO-derived peptide having the specific amino acid sequence set forth in SEQ ID NO: 1. The kit may optionally contain a pharmaceutically acceptable excipient as part of the composition.
The claim primarily protects the provision of a kit containing a composition with a cyclic synthetic EPO-derived peptide of SEQ ID NO: 1, optionally formulated with pharmaceutically acceptable excipients.
Stated Advantages
The EPO-derived peptides provide low manufacturing costs, low immunogenicity, and high stability compared to whole molecule erythropoietin.
These peptides are devoid of hematopoietic effects, avoiding complications such as heart attack and stroke associated with whole molecule EPO.
Treatment with these peptides, such as JM4, demonstrated robust immunomodulatory effects including modulation of T cell ratios and down-regulation of pro-inflammatory cytokine production.
In animal models, these peptides delayed onset and progression of neurodegenerative disease, limited cognitive impairment, reduced pathological hallmarks, and prolonged survival with a favorable side effect profile compared to whole EPO.
Documented Applications
Treatment of neurodegenerative diseases, including Alzheimer's disease.
Delaying the onset or progression of neurodegenerative diseases in subjects.
Limiting cognitive impairment in subjects suffering from neurodegenerative diseases.
Prolonging survival of subjects suffering from neurodegenerative diseases.
Use in pharmaceutical compositions and kits containing EPO-derived peptides for administration to subjects.
Interested in licensing this patent?